Proudly sponsored by

Sinovac to trial Covid-19 vaccine in SA children in global study

The study will evaluate the efficacy, immunogenicity and safety of the CoronaVac vaccine on children and adolescents aged 6 months to 17 years, the firms said in a statement.
Image: Bloomberg

China’s Sinovac Biotech will trial its Covid-19 vaccine in children and adolescents in South Africa as part of a global Phase III study, Sinovac and local partner Numolux Group said on Thursday.

The study will evaluate the efficacy, immunogenicity and safety of the CoronaVac vaccine on children and adolescents aged 6 months to 17 years, the firms said in a statement.

Moneyweb Insider INSIDERGOLD

Subscribe for full access to all our share and unit trust data tools, our award-winning articles, and support quality journalism in the process.

Choose an option:

R63 per month
R630 per year SAVE R126

You will be redirected to a checkout page.
To view all features and options, click here.

A monthly subscription is charged pro rata, based on the day of purchase. This is non-refundable and includes a R5 once-off sign-up fee.
A yearly subscription is refundable within 14 days of purchase and includes a 365-day membership.

Click here for more information.

The global trial will enrol 14 000 participants across Chile, the Philippines, Malaysia and Kenya, including 2 000 in South Africa, they said.

The trial has been approved by South African drugs regulator SAHPRA, and the first child will be vaccinated at the MeCRU Clinical Research Unit based at the Sefako Makgatho Health Sciences University on Friday.

“The primary objective of the study is to evaluate the efficacy of two doses of CoronaVac against confirmed symptomatic Covid-19 cases in children and adolescents … efficacy will also be evaluated against hospitalisation and severe Covid-19,” Sinovac and Numolux said.

The South African government has said it is considering using the CoronaVac vaccine in its immunisation programme alongside shots developed by Pfizer and Johnson & Johnson which have been administered so far.

SAHPRA gave conditional authorisation for use of Sinovac’s vaccine in July.

But last month a senior health official told Reuters the government was looking for more information from the Chinese company on how its vaccine performs against the Delta coronavirus variant as well as in populations with HIV.

South Africa’s vaccination campaign started slowly due to onerous negotiations with pharmaceutical companies and the emergence of the Beta coronavirus variant which scuppered plans to use AstraZeneca’s shot from February.

So far, more than 10.3 million of its roughly 60 million people have received at least one dose of vaccine, equivalent to around 17% of the population.

COMMENTS   6

Sort by:
  • Oldest first
  • Newest first
  • Top voted

You must be signed in to comment.

SIGN IN SIGN UP

Very disturbing that human beings are being experimented upon like this!

Please someone, anyone for that matter, tell me that this ‘vaccine’ has been tested and used on Chinese children, and that we have a report on its efficacy that stem from peer reviewed studies and other world peers that are non-Sinovac ralated.
The last time I checked, China itself had said that their vaccine had levels of efficacy that were not encouraging, being that they were below 70% if at that. So, why are they in a hurry to give it to children under the ANC government?
No, monkeying around with liquid with unknown properties and a sharp syringe near my child. Let us vaccinate all the children of all the poloticians with this Sinovac trial vaccine. That may yet rid us of … hereditary politican baffoons!

Well its an opportunity to sell your child!!!

Like the Chinese don’t have children???

Go for it. Money is hard to come by. Not uncommon in these parts. Guess its better than being a sex slave.

China loves you and only wants what is best for your children.

Professor Wei Shen Lim, Chair of COVID-19 Immunisation for the JCVI, said:

Children aged 12 to 15 years old with underlying health conditions that put them at higher risk of severe COVID-19 should be offered COVID-19 vaccination. The range of underlying health conditions that apply has recently been expanded.

For otherwise healthy 12 to 15 year old children, their risk of severe COVID-19 disease is small and therefore the potential for benefit from COVID-19 vaccination is also small. The JCVI’s view is that overall, the health benefits from COVID-19 vaccination to healthy children aged 12 to 15 years are marginally greater than the potential harms.

Taking a precautionary approach, this margin of benefit is considered too small to support universal COVID-19 vaccination for this age group at this time. The committee will continue to review safety data as they emerge.

I would much rather take the CoronaVac jab than any of the mRNA types. It’s based on decades-old proven tried-and-tested medical principles and is a ‘true vaccine’ (a de-activated part of the SARS Cov 2 virus similar to most flu vaccines we know. I’m not too concerned about efficacy (it’s efficacy at 70% is similar to most other similar tech flu shots). The mRNA shots loose efficacy at a great rate after 6 months in any event (refer to peer reviewed studies in Israel and UK). If this jab will give me my ‘vax certificate’ I’ll take it. Including my kids in a trial will also not be an issue – again, it’s based on tech that’s been proven over many decades and no, it’s not ‘Chinese tech’…

End of comments.

LATEST CURRENCIES  

USD / ZAR
GBP / ZAR
EUR / ZAR
BTC / USD

Podcasts

INSIDER SUBSCRIPTIONS APP VIDEOS RADIO / LISTEN LIVE SHOP OFFERS WEBINARS NEWSLETTERS TRENDING PORTFOLIO TOOL CPD HUB

Follow us:

Search Articles:
Click a Company: